Anixa Biosciences Inc
ANIXNasdaq
$3.40
↑ +2.4%Jul 17 close · end-of-day
Price
1Y↑ +1.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$114.2M
Enterprise Value
$100.5M
P/E
—
P/S
—
P/B
7.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$10.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-69.3%
ROIC
-1068.8%
Debt / Equity
—
Net Cash
$13.7M
Return 1Y
+1.5%
Company profile
Anixa Biosciences, Inc. develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company is also developing immuno-therapy drugs against cancer.
- CEO
- Amit D. Kumar
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 5
- Headquarters
- California
- Website
- anixa.com
Earnings
ANIX Q2 2026 Earnings
Period ends 2026-04-30
MetricActualYoY
Revenue——
Diluted EPS-$0.07↓ -22.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $512,000.00 | — | $210,000.00 | $210,000.00 | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$10.0M | -$13.1M | -$13.9M | -$11.0M | -$13.8M | -$11.7M |
| Net income | -$10.0M | -$13.0M | -$13.6M | -$9.8M | -$12.6M | -$10.9M |
| Diluted EPS | — | — | $0.45 | -$0.32 | -$0.39 | -$0.34 |
| Operating cash flow | -$6.2M | -$4.9M | -$6.5M | -$6.2M | -$7.3M | -$7.2M |
| Free cash flow | -$6.2M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -2565.6% | — | -5243.3% | -6586.2% | — |
| Net margin | — | -2530.1% | — | -4671.9% | -5978.1% | — |
| Line item | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.6M | -$3.2M | -$3.4M | -$3.0M | -$2.4M | -$2.9M | -$2.7M | -$2.6M |
| Net income | -$3.3M | -$2.9M | -$3.2M | -$2.8M | -$2.3M | -$2.7M | -$2.6M | -$2.5M |
| Diluted EPS | -$0.10 | -$0.09 | -$0.10 | -$0.09 | -$0.07 | -$0.08 | -$0.08 | -$0.07 |
| Operating cash flow | -$2.6M | -$927,000.00 | -$2.9M | -$1.5M | -$1.5M | -$1.3M | -$2.6M | -$1.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Titterton Lewis H jr | Buy | 2,797 | $3.28 | $9,174.16 | filing |
| 2026-07-10 | KUMAR AMIT· Chief Executive Officer | Buy | 5,000 | $3.04 | $15,200.00 | filing |
| 2026-06-16 | Titterton Lewis H jr | Buy | 2,836 | $2.64 | $7,487.04 | filing |
| 2026-06-12 | KUMAR AMIT· Chief Executive Officer | Buy | 21,000 | $2.50 | $52,500.00 | filing |
| 2026-01-28 | Baskies Arnold M | Buy | 10,000 | $3.04 | $30,400.00 | filing |
| 2025-12-15 | Titterton Lewis H jr | Option exercise | 16,000 | $2.92 | $46,720.00 | filing |
| 2025-10-30 | KUMAR AMIT· Chief Executive Officer | Tax withholding | 169,439 | $4.06 | $687,922.34 | filing |
| 2025-10-30 | KUMAR AMIT· Chief Executive Officer | Option exercise | 200,000 | $2.92 | $584,000.00 | filing |
| 2025-07-31 | Titterton Lewis H jr | Buy | 10,000 | $3.08 | $30,800.00 | filing |
| 2025-07-30 | KUMAR AMIT· Chief Executive Officer | Buy | 5,000 | $3.16 | $15,800.00 | filing |
| 2025-07-18 | Baskies Arnold M | Buy | 5,000 | $3.39 | $16,950.00 | filing |
| 2025-07-11 | Titterton Lewis H jr | Buy | 10,000 | $3.14 | $31,400.00 | filing |
| 2025-07-11 | KUMAR AMIT· Chief Executive Officer | Buy | 5,000 | $3.15 | $15,750.00 | filing |
Latest 13 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.